| Project/Area Number |
26670759
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine |
|---|
Principal Investigator |
SOTOZONO CHIE 京都府立医科大学, 医学(系)研究科(研究院), 教授 (30216585)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
羽室 淳爾 京都府立医科大学, 医学(系)研究科(研究院), 特任教授 (80536095)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 角膜内皮細胞 / エネルギー代謝応答 / 解糖系 / ミトコンドリア / 代謝リモデリング / miRNA / 細胞相転移 / ヒト角膜内皮細胞 / 相転移 / CD44 / SASP / エネルギー代謝経路 / 細胞亜集団 / 培養ヒト角膜内皮細胞 / EMT / メタボローム解析 / 解糖系エネルギー代謝 |
|---|
| Outline of Final Research Achievements |
In this study, we found the way, using the culture supernatants, to discrimiーnate SPs in cHCECs in terms of their secretory metabolites, and found that the CST SPs exhibited the disposition to the anaerobic glycolysis instead of mitoc-hondria-dependent OXPHOS. The study on the secretory metabolites assigned the cHCEC SPs distinct in the expression levels of surface CD44 antigen. Transition from oxidative metabolism into glycolysis is a prerequisite for reprogramming to the pluripotent state. Conversely, redirection of pluripotency into defined lineages requires mito- chondrial biogenesis and maturation of efficient oxidative energy generati- on.The reduction of glycolysis might be triggered by downregulation of the cMyc pathway.Our novel findings provide evidence of a possible link between metabo-lic regulation in the corneal endothelium and the development of more effective targeted therapies to treat patients with bullous keratopathy, including FECD.
|
